A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

ClinicalTrials.gov ID: NCT02205333

Public ClinicalTrials.gov record NCT02205333. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given as monotherapy and in combination with tremelimumab, MEDI4736 (durvalumab), or rituximab in participants with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL). Tremelimumab and MEDI4736 (durvalumab) will be tested with MEDI6469 in a set of participants with advanced solid tumors while rituximab will be tested with MEDI6469 in participants with DLBCL. MEDI6469 will be tested as monotherapy in participants with advanced solid tumors.

Study identification

NCT ID: NCT02205333
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: MedImmune LLC; Industry
Enrollment: 48 participants

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 13, 2014 (Actual)
Primary completion: Apr 8, 2016 (Actual)
Completion: Apr 8, 2016 (Actual)
Last update posted: Jun 28, 2017

2014 – 2016

United States locations

U.S. sites: 13
U.S. states: 12
U.S. cities: 13

Facility	City	State	ZIP	Site status
Research Site	Scottsdale	Arizona	85259	—
Research Site	Sacramento	California	95817	—
Research Site	Santa Monica	California	90404	—
Research Site	Washington D.C.	District of Columbia	20007	—
Research Site	Tampa	Florida	33612	—
Research Site	Chicago	Illinois	60611	—
Research Site	Detroit	Michigan	48202	—
Research Site	Las Vegas	Nevada	89169	—
Research Site	Hackensack	New Jersey	7601	—
Research Site	Huntersville	North Carolina	28078	—
Research Site	Portland	Oregon	97213	—
Research Site	Memphis	Tennessee	38120	—
Research Site	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02205333, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 28, 2017 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02205333 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →